lymphoma Jul 13, 2022 Mission Bio Working to Bring Tapestri Single-Cell Sequencing Platform to Precision Oncology Premium Jul 11, 2022 Legend Biotech Shutters Trial of CD4-Directed CAR T-Cell Therapy for T-Cell Lymphoma Jun 29, 2022 Leukemia and Lymphoma Society Launches Master Protocol Trial in Childhood Leukemia Jun 28, 2022 European Commission Approves Gilead Sciences' Yescarta for Follicular Lymphoma Patients Jun 27, 2022 FDA Approves Bristol Myers Squibb's Breyanzi for Second-Line Lymphoma Patients Jun 27, 2022 Ipsen Acquires Epizyme, Garners Tazverik, Other Oncology Assets Jun 24, 2022 Calithera Biosciences Begins Phase II Trial of Mivavotinib in DLBCL Jun 20, 2022 BMS Submits Breyanzi for European Approval as Second-Line Lymphoma Treatment Jun 15, 2022 Kymera Therapeutics Begins Phase I Trial in MYD88-Mutant Lymphoma May 31, 2022 Novartis' Kymriah Nabs FDA Approval in Refractory Follicular Lymphoma May 27, 2022 BMS Shows Breyanzi Benefit in Stem Cell Transplant-Ineligible LBCL May 26, 2022 TIGIT Blockade Could Be Key to Improving Success Rates in CAR T-Cell Therapy Premium May 25, 2022 Umoja Biopharma Enters Clinical Stage With Seattle Children's CAR T-Cell Trial Premium May 4, 2022 Novartis Nabs European Approval for Kymriah in Follicular Lymphoma Apr 26, 2022 Novartis Q1 Revenues Grow 1 Percent Amid Organizational Restructuring, Shifting Growth Drivers Apr 26, 2022 Mustang Bio Expanding Phase I/II Trial of Anti-CD20 CAR T-Cell Therapy Apr 13, 2022 FDA Lifts Partial Clinical Holds for Some Gilead Trials Apr 10, 2022 AACR Data Show Donor NK Cells Plus Bispecific Antibody Could Benefit CD30-Positive Lymphoma Patients Premium Apr 5, 2022 Bristol Myers Squibb's Breyanzi Approved in Europe for Lymphoma Patients Apr 4, 2022 FDA Approves Gilead's Yescarta as Second-Line Treatment for Large B-Cell Lymphoma Patients Load More Breaking News FDA Approves Taiho Oncology's Lytgobi for FGFR2-Rearranged Bile Duct Cancer Gladstone Institute Joins With Parker Institute on New Center to Study CRISPR-Based Cell Therapies Meliora Therapeutics Raises $11M in Seed Financing In Brief This Week:Â Verismo Therapeutics, Fore Biotherapeutics, Merck, Caris Life Sciences Tumor-Only Sequencing Found to Overestimate Mutational Burden in Non-European Patients Atara Biotherapeutics to Net $30M From Pierre Fabre for European Tab-Cel Approval
